Bayer CEO Anderson sticking out firm’s revitalization scheme
With Bayer’s pharma sales growth lagging behind its crop science and consumer health divisions in the second quarter,…
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Study to evaluate OP-3136, Olema’s novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to…